The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …

Approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML) harbor
mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

FLT3 mutations occur in 20–35% patients with newly diagnosed (ND) acute myeloid
leukemia (AML) and confer a higher risk of relapse and inferior overall survival (OS). Given …

BCL-2 inhibition has been shown to be effective in acute myeloid leukemia (AML) in
combination with hypomethylating agents or low-dose cytarabine. However, resistance and …

Purpose: To evaluate efficacy and safety of venetoclax+ azacitidine among treatment-naïve
patients with FLT3-mutant acute myeloid leukemia. Patients and Methods: Data were pooled …

In older/unfit newly diagnosed patients with FLT3 mutated acute myeloid leukemia (AML),
lower intensity chemotherapy (LIC) in combination with either a FLT3 inhibitor or with …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …